相似文献
1
Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3C-CX3CR1 interaction and expression of substance P.
J Virol. 2003 Sep;77(18):9831-44. doi: 10.1128/jvi.77.18.9831-9844.2003.
2
Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.
J Virol. 2004 Jun;78(11):6024-32. doi: 10.1128/JVI.78.11.6024-6032.2004.
3
Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice.
J Virol. 2010 Jan;84(2):1148-57. doi: 10.1128/JVI.01755-09. Epub 2009 Oct 28.
4
Vbeta14(+) T cells mediate the vaccine-enhanced disease induced by immunization with respiratory syncytial virus (RSV) G glycoprotein but not with formalin-inactivated RSV.
J Virol. 2004 Aug;78(16):8753-60. doi: 10.1128/JVI.78.16.8753-8760.2004.
5
Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses.
J Immunol. 2006 Feb 1;176(3):1600-8. doi: 10.4049/jimmunol.176.3.1600.
6
Mutating the CX3C Motif in the G Protein Should Make a Live Respiratory Syncytial Virus Vaccine Safer and More Effective.
J Virol. 2017 Apr 28;91(10). doi: 10.1128/JVI.02059-16. Print 2017 May 15.
7
The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P.
J Virol. 2003 Jun;77(11):6580-4. doi: 10.1128/jvi.77.11.6580-6584.2003.
8
Contribution of respiratory syncytial virus G antigenicity to vaccine-enhanced illness and the implications for severe disease during primary respiratory syncytial virus infection.
Pediatr Infect Dis J. 2004 Jan;23(1 Suppl):S46-57. doi: 10.1097/01.inf.0000108192.94692.d2.
9
Both immunisation with a formalin-inactivated respiratory syncytial virus (RSV) vaccine and a mock antigen vaccine induce severe lung pathology and a Th2 cytokine profile in RSV-challenged mice.
Vaccine. 2000 Nov 22;19(7-8):982-91. doi: 10.1016/s0264-410x(00)00213-9.
10
Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains.
Viral Immunol. 2012 Jun;25(3):193-203. doi: 10.1089/vim.2011.0094. Epub 2012 May 2.
引用本文的文献
1
Exploring Therapeutic Targets From Spreading Patterns Against Respiratory Syncytial Virus.
FASEB J. 2025 Jul 31;39(14):e70858. doi: 10.1096/fj.202500509RR.
2
Layer-by-Layer Microparticle Vaccines Containing a S177Q Point Mutation in the Central Conserved Domain of the RSV G Protein Improves Immunogenicity.
Viral Immunol. 2025 Apr;38(3):107-119. doi: 10.1089/vim.2024.0084. Epub 2025 Mar 24.
3
4
Immunogenicity and protective efficacy of an RSV G S177Q central conserved domain nanoparticle vaccine.
Front Immunol. 2023 Jun 29;14:1215323. doi: 10.3389/fimmu.2023.1215323. eCollection 2023.
5
Immune Prophylaxis Targeting the Respiratory Syncytial Virus (RSV) G Protein.
Viruses. 2023 Apr 27;15(5):1067. doi: 10.3390/v15051067.
6
Microparticle RSV Vaccines Presenting the G Protein CX3C Chemokine Motif in the Context of TLR Signaling Induce Protective Th1 Immune Responses and Prevent Pulmonary Eosinophilia Post-Challenge.
Vaccines (Basel). 2022 Dec 5;10(12):2078. doi: 10.3390/vaccines10122078.
7
RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses.
NPJ Vaccines. 2022 Dec 19;7(1):168. doi: 10.1038/s41541-022-00591-w.
8
Probenecid Inhibits Respiratory Syncytial Virus (RSV) Replication.
Viruses. 2022 Apr 27;14(5):912. doi: 10.3390/v14050912.
9
Structure-Based Design and Antigenic Validation of Respiratory Syncytial Virus G Immunogens.
J Virol. 2022 Apr 13;96(7):e0220121. doi: 10.1128/jvi.02201-21. Epub 2022 Mar 10.
10
Structural Characterization of Ectodomain G Protein of Respiratory Syncytial Virus and Its Interaction with Heparan Sulfate: Multi-Spectroscopic and In Silico Studies Elucidating Host-Pathogen Interactions.
Molecules. 2021 Dec 6;26(23):7398. doi: 10.3390/molecules26237398.
本文引用的文献
1
Chemokines: attractive mediators of the immune response.
Semin Immunol. 2003 Feb;15(1):5-14. doi: 10.1016/s1044-5323(02)00123-9.
2
Differential migration behavior and chemokine production by myeloid and plasmacytoid dendritic cells.
Hum Immunol. 2002 Dec;63(12):1164-71. doi: 10.1016/s0198-8859(02)00755-3.
3
Fractalkine transgene induces T-cell-dependent antitumor immunity through chemoattraction and activation of dendritic cells.
Int J Cancer. 2003 Jan 10;103(2):212-20. doi: 10.1002/ijc.10816.
4
Substance P receptor expression on lymphocytes is associated with the immune response to respiratory syncytial virus infection.
J Neuroimmunol. 2002 Aug;129(1-2):141-53. doi: 10.1016/s0165-5728(02)00169-8.
5
Fractalkine and fractalkine receptors in human neurons and glial cells.
J Neurosci Res. 2002 Aug 1;69(3):418-26. doi: 10.1002/jnr.10304.
6
Potential therapeutic implications of new insights into respiratory syncytial virus disease.
Respir Res. 2002;3 Suppl 1(Suppl 1):S15-20. doi: 10.1186/rr184.
7
Fractalkine expression on human renal tubular epithelial cells: potential role in mononuclear cell adhesion.
Clin Exp Immunol. 2002 Jul;129(1):150-9. doi: 10.1046/j.1365-2249.2002.01906.x.
8
Respiratory syncytial virus immunobiology and pathogenesis.
Virology. 2002 May 25;297(1):1-7. doi: 10.1006/viro.2002.1431.
9
Functional effects of eotaxin are selectively upregulated on IL-5 transgenic mouse eosinophils.
Inflammation. 2002 Jun;26(3):111-9. doi: 10.1023/a:1015548414274.
10
Neutralizing anti-F glycoprotein and anti-substance P antibody treatment effectively reduces infection and inflammation associated with respiratory syncytial virus infection.
J Virol. 2002 Jul;76(14):6873-81. doi: 10.1128/jvi.76.14.6873-6881.2002.
Zotero 插件